How East Asian PhD founders and spinouts, and Asian TTOs, can navigate the US commercialization ecosystem.
This post is not a general GTM analysis for Asian companies entering the US market. It is written specifically for research-backed ventures and university spinouts; that is, founders who have built something out of research, have institutional credibility at home, and now need to establish early commercial traction in the US. The pattern I’m describing, however, is not new, and the lessons from the first generation of Asian companies trying to enter the US market still apply directly, as do more recent cases.
During the 1990s I worked with some of the first Chinese state-owned enterprises looking to privatize and enter international markets, which was the beginning of what Beijing would later formalize as the “Going Out” strategy. These companies were usually flying blind: trying to build an international playbook from scratch, expanding into markets with no framework to understand them, and operating with a Soviet-influenced state-led mindset about how business works, which didn’t work in US markets (though it did in other countries).
Over the years, the difference between those that navigated US market entry successfully and those who failed wasn’t about technology quality or the scale of commercial opportunity; it was about execution. Lenovo’s acquisition of IBM’s PC business in 2004 succeeded partly because IBM had strong strategic interests in the Chinese market and made it happen. TCL’s acquisition of Thomson’s shaky TV business that same year was hamstrung because its managers wrongly assumed that what made TCL a domestic champion in China would transfer to the West.
Years later, between 2018 and 2023, Chinese EdTech sector’s US experience repeated a similar pattern. Leading companies such as TAL Education, New Oriental, and Gaotu Techedu lost billions in market value (with heavy US investment) during a regulatory crackdown. This came without warning, in July 2021, when China’s State Council banned for-profit tutoring in core school subjects. For PhD spinout founders, the lesson is not about EdTech but rather the regulatory risk that any Chinese-origin company faces.
Meanwhile in the US, Chinese firms marketing directly to US consumers discovered that their test-prep economics could not survive US customer acquisition cost, and platforms that handled US student data had problems complying with both China’s Personal Information Protection Law (“PIPL”), which mandates strict data localization requirements that are not compatible with US privacy regulation. This case of Edtech illustrates three distinct fault lines at once, across geopolitical, commercial, and regulatory angles, and the difficulties involved, even with well-resourced companies.
So what does this mean for East Asian PhD founders trying to access the US market with start-ups today? What are some of the assumptions that worked at home but failed (or were costly errors) in the US? And what does the US market require that most Asian founders, and Asia-based universities and TTOs, may not know about?
Before examining these issues, note that cross-border expansion challenges are not uniform across East Asian countries. A Singaporean founder faces primarily commercial and proof point translation challenges in US, but not significant regulatory or geopolitical complications. Korean or Japanese founders may struggle with relationship and timeline gaps, as well as basic commercial challenges. Chinese founders, unfortunately, will face all of those issues plus an additional security layer that includes CFIUS scrutiny, ODI Regulations, and data sovereignty conflicts. I have noted this additional layer throughout this post where relevant.
What are some specific challenges to consider?
Treat the US TTO as a partner, not a gatekeeper
East Asian founders may reasonably assume that the institution controlling the IP also controls access to the market. In Korea, state research institutions and commercial gatekeeper can be the same entity. In China, the SOE and the regulatory framework are often symbiotic: the state can drive commercial applications for deep tech and related areas, and is involved in the process. In Japan, the keiretsu corporate network facilitates commercialization through relationships. Japanese universities do have TTOs, and their infrastructure has grown significantly, with an estimated 85% of top Japanese academic institutions with investment vehicles supporting spinouts (UTokyo IPC alone manages $420M). However, the keiretsu relationship network remains the dominant commercialization gateway in practice, and most Japanese TTOs operate within that framework.
US TTOs often operate differently. Their mandate is to license technology, generate revenue, and get research commercialized. That’s how they’re incentivized. Which also means that approaching a US TTO requires a clear commercialization plan, a credible founding team, and a good understanding of licensing terms. Asia-based founders should engage TTOs like a commercial negotiation.
Several US university programs are explicitly designed for international founders and will help to make this path easier. Berkeley SkyDeck, with 2/3 of its startups historically founded outside the US, expanded eligibility in 2024 beyond UC Berkeley affiliation, which effectively makes it accessible to international founders with US research connections. Johns Hopkins Technology Ventures is a full commercialization and entrepreneurship hub covering IP licensing and startup development, with strong international collaboration. Finally, MIT’s MISTI program operates in the Asia-Pacific through MIT-Singapore, MIT-China, and MIT-Australia and New Zealand. MIT also has global seed funds that enable new research collaborations between MIT faculty and international counterparts. These are just three examples; the table below summarizes terms and a few other entities.
Another tactic is for founders to target existing institutional relationships, such as a joint research programs, visiting researcher relationships, co-authored publications or a dual-degree connection between universities. Any of these connections can create a warm pathway into the US TTO system, and should be leveraged for maximum impact.
In terms of what actually can be done with licensing to TTOs, a common question from Asian founders is, “can I license my technology to a US entity and retain control from Asia?” The answer is yes, provided it is structured intelligently. For example, a US entity can conduct business in the US while the founding team remains based in Asia, if the entity has a US-based commercial representative or early team member. This assumes that the licensing terms don’t require IP to physically move and that the entity structure satisfies US investor and grant requirements (if a grant it sought). Hence, US engagement for Asia-based founders may not require relocation immediately under specific terms.
Summary: Approach the US TTO as a potential partner with a commercialization plan. Identify US universities with existing research relationships to your institution first and use those connections to gain entry. Make the licensing conversation part of a broader partnership.
Establish the US entity before everything else
Assuming that the existing home country entity can serve as the commercial vehicle in the US is generally a mistake.
Most US institutional investors, whether they be angels, seed funds, or VCs, will not invest in a foreign entity. Sure, some global funds with international vehicles, such as Sequoia’s Asia vehicles or GGV, have structures that can accommodate foreign entities at early stages, but these are exceptions. A Delaware C-corp is often standard prerequisite for US institutional capital, and the primary choice for deep tech and related spinouts.
How might this be executed effectively?
For Asia-based founders, the so-called “Delaware flip,” or reincorporating a foreign company as a Delaware C-corp through a share exchange that makes the Delaware entity the parent of the original foreign entity, is a well worn path. Beyond capital access, a US entity can unlock non-dilutive funding such as SBIR and NIH grants, which are available to US-based entities regardless of founder citizenship. In our case here, a Delaware C-corp can also accept investment from Korean, Japanese, and Singaporean investors without complication, although Chinese investors in certain sectors may trigger CFIUS review depending on ownership percentage and the technology’s sensitivity (eg. AI, advanced materials, or dual-use technologies).
For founders who are also in the US on a visa, such as an F-1, H-1B, or otherwise, the entity structure question intersects directly with the immigration question I covered in a past Founder Brief. That is, the governance structure under US law requires self-employment authorization, which US investor will expect as well. They should be pursued together.
The timing of establishing a US entity should also be considered carefully. If you flip (to Delaware) too early, such as before the IP ownership question is resolved, a TTO license, or securing co-inventor relationships, expect complications that may be expensive to unwind. If you flip too late, after an investor conversation has started or a grant deadline has passed, or with a US pilot agreement requiring a US entity, you will lose momentum.
One specific note on China: Chinese founders face increasing but not insurmountable challenges in the US, the latest being a July 2026 ODI Regulations which may limit transferring IP from a Chinese entity to a US entity. They will get it from both sides; specialist legal advice is essential before proceeding.
Summary: Establish the Delaware C-corp before engaging US investors conversation, a grant application, and a US TTO licensing discussion. Think of the entity structure as a prerequisite for accessing every layer of the US capital and commercial stack.
Build US proof points before the pitch
An Asia-based founder I’m currently advising built an AI assessment platform out of his university research in Asia. The company has strong technology and institutional validation through government partnerships, ministry recognition, and a range of university and corporate clients. When he arrived in the US market, he assumed that this track record would open doors with US buyers, but it wasn’t so straightforward.
Does a procurement officer at a US school district know how to evaluate a ministry endorsement? Or a US corporate L&D buyer understanding a university partnership the way an Asian buyer might, who is familiar with that particular name? The answer in both cases is no. US buyers want to see pilot data from US institutions, local customers, and to know that a specific technology or solution is proven to work in a US regulatory and operational environment. The lesson here: institutional credibility is not always portable across markets. What may be validated in Asia is a necessary but not sufficient condition for US commercial success.
If getting a US pilot can help establish more de-risking, you will need to budget for time. How long does it take to get in place? Based on my experience, typically three to six months for a well-prepared approach to a receptive institutional partner (if the technology requires regulatory clearance before deployment that’s a different story; make sure you know). In terms of partnerships, US institutions that are generally open to piloting with Asian founders are research universities with existing international faculty relationships, community colleges with workforce development mandates and lower procurement barriers than K-12 districts, corporate innovation groups at multinationals with Asian operations, and hospital systems affiliated with academic medical centers (and research partnerships).
Summary: Consider your initial US engagement through a pilot. Before approaching US investors or enterprise buyers, identify one US institutional partner willing to run a structured pilot. That pilot generates the US proof point that opens a pathway to all other US commercial conversations.
Enter the capital stack at the right level
While relationship capital can typically open doors in Asian capital markets, US investors will rely on evidence to consider a cross-border start-up: traction, team, market size, IP defensibility, commercial proof. This is why an accelerator entry point might be more strategically impactful than a direct VC approach for most East Asian founders without existing US relationships.
Accelerators are most reliable entry mechanism. Y Combinator explicitly accepts international founders, and YC acceptance creates an immediate US credibility signal that most other programs cannot replicate. Berkeley SkyDeck, as noted earlier, has heavy foreign founder presence and provides access to 500,000 Berkeley alumni, and a Demo Day attended by 850+ investors. MassChallenge takes zero equity and charges zero fees, making it one of the most accessible non-dilutive accelerator in the US for early-stage international founders, and a particularly strong launchpad for life sciences and medtech founders from Asia given the density of academic medical centers in Boston.
And geography matters for East Asian founders. Bay Area investors tend to be the most globally minded and AI-literate, and a natural channel for most deep tech and AI ventures. New York has a strong enterprise software and fintech investor base with strong international vibes, and may be a better entry point for founders targeting financial services, media, or corporate enterprise buyers. Boston or Southern California is among the most accessible regions for life sciences and medtech founders given academic medical center density and an internationally oriented life sciences investor base.
But remember, the Delaware C-corp is often expected before applying to most US accelerators and before any US investor will issue a term sheet. Plan accordingly.
Summary: Apply to a US accelerator before approaching US VCs directly. Accelerator acceptance is the US credibility signal that makes the subsequent investor conversation possible. Establish the Delaware entity before applying.
Map the regulatory risk in both directions
The earlier EdTech story’s most instructive lesson is not about consumer behavior or capital market access, but about regulatory risk.
For East Asian PhD founders, regulatory risk runs in both directions simultaneously. US regulatory requirements, such as FDA for medtech and life sciences, FTC for consumer-facing AI, CFIUS for certain investment structures involving foreign nationals, are well-documented and navigable. Home country constraints on US market engagement are less well-mapped but can be equally consequential.
For example, Korea’s export control framework affects certain advanced materials and semiconductor technologies. Japan’s Foreign Exchange and Foreign Trade Act has specific provisions affecting technology transfer in strategic sectors. Singapore’s constraints are minimal, one of the structural reasons it functions as the most accessible Asian market gateway. China’s constraints are the most significant: the July 2026 ODI Regulations target offshore structuring explicitly, the PIPL creates data sovereignty conflicts for any platform handling both Chinese and US user data, and CFIUS scrutiny of Chinese-affiliated investment structures has intensified significantly since 2020 and shows no signs of easing.
On CFIUS specifically: Korean, Japanese, and Singaporean founders face minimal scrutiny for most technology sectors, since a CFIUS review becomes relevant only in genuinely sensitive areas such as advanced semiconductors, certain AI applications with defense relevance, quantum computing, and dual-use biotechnology. Chinese founders face a categorically different situation where CFIUS scrutiny applies more broadly, is triggered at lower ownership thresholds, and has become significantly less predictable since 2020. If you are a Chinese founder or have Chinese investors in your cap table, CFIUS mapping is not optional and will require advice.
For all East Asian founders, the practical implication is the same: TTO license sub-licensing provisions, entity structure, and pilot agreement data terms all need to be reviewed against both the US regulatory framework and the home country constraints simultaneously.
The correction: Answer two questions before the first US commercial conversation: what does the US regulatory environment require from my technology and entity structure? And what does my home country regulatory environment permit me to do with US commercial relationships? Clear both before proceeding.
ONE ACTION
Act on one question per theme before engaging the US market:
Treat the US TTO as a partner: Have you identified which US universities have existing research relationships with your home institution? Perhaps a co-author, a joint grant, a visiting researcher, or any existing connection is a warm entry point?
Establish the US entity: Is the Delaware C-corp established before the first US investor conversation, grant application, and TTO licensing? If not, that is the first action.
Build US proof points: Have you identified one US institutional partner willing to run a structured pilot before you approach investors or enterprise buyers? The pilot generates the proof point you need to access other growth levers.
Enter the capital stack correctly: Have you applied to, or researched, a US accelerator before approaching VCs or investors directly? . Accelerator acceptance is a de-risking signal that makes the subsequent investor conversation significantly easier.
Map both regulatory environments: Have you mapped your home country’s constraints on US commercial engagement (such as export controls, data sovereignty, ODI compliance) alongside US regulatory requirements?
Notwithstanding these challenges, the US market is more accessible to East Asian PhD founders than the current geopolitical headlines suggest. But it requires a different commercial logic, a different entity structure, a different evidence base, and a different capital entry sequence than what is expected in most Asian commercialization ecosystems.
Knowing the difference before you arrive will significantly increase your chances of success.
A note for Asian TTOs
Here are five questions worth asking at the licensing stage for any spinout founder targeting the US market:
Has the founder established a Delaware entity before the first US capital conversation? Have existing US university research connections been mapped as warm entry points into the US TTO system? Does the founder understand that Asian institutional credibility requires translation into US proof points before approaching US buyers or investors? Has the founder applied to a US accelerator before approaching US VCs directly? And has the home country regulatory environment — including CFIUS implications for Chinese-affiliated cap tables, been mapped alongside US regulatory requirements?
These are not questions most Asian TTOs currently ask. Founders who enter the US market without this framework will discover the gaps at the worst possible moment, and be disadvantaged in the US market. That can be prevented.
The PhD Founder Brief is published weekly by Todd Maurer — founder of Edunomix, owner of VersatilePhD. Commercialization intelligence for research-backed ventures and the institutions that support them.
Need advice? Work with Edunomix → | TTO or university innovation office? Bring the PROVE sequence to your cohort → | Browse all issues → edunomix.com/brief
- Sources
Wharton Knowledge: “Ambition vs. Reality: What China’s High Profile Global Acquisitions Have in Common” (December 2006) - Business Insider: “US-listed Chinese stocks crackdown” (July 2021)
- Forbes: “China Online Ed Stocks Fizzled” (January 2022)
- WashU Law Review: “EdTech Sovereignty and the Future of Transatlantic Data Law” (January 2026)
- IdeaProof: “EdTech Failure Cases”
- Berkeley SkyDeck: Programme Overview 2026
- Berkeley SkyDeck: “Batch 19 Applications — Expanded Eligibility” (July 2024) · MIT MISTI: Asia-Pacific Programme Overview
- MIT News: “How MIT Sandbox has turned student ideas into $8.7 billion in global impact” (August 2026)
- Johns Hopkins Technology Ventures: Overview 2026
- National Foundation for American Policy: “Immigrant Founders of US Billion-Dollar Startups” (July 2022)
- Peony: “Top 20 Startup Accelerators Worldwide” (June 2026)
- Elev-X: “Best Startup Incubators in the US” (June 2026)
- PhD Founder Brief: past issues